Standout Papers
Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)
2001 StandoutScience
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
2010 Standout
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
2010 Standout
Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis.
1992
No health without mental health
2007 Standout
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
1998 StandoutNature
Thiazolidinediones
2004 Standout
DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart Disease
1998
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
2005
Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment
1994
Diabetic Foot Ulcers and Their Recurrence
2017 Standout
The Serum Paraoxonase Activity in Patients with Chronic Renal Failure and Hyperlipidemia
1998
Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
2002 Standout
Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome
2000
Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus
2000
The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
2001 Standout
Cholesterol-lowering effects of dietary fiber: a meta-analysis
1999 Standout
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
1998
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia
2004
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Twenty‐four Hour Blood Pressure and Heart Rate Profiles of Diabetic Patients with Abnormal Cardiovascular Reflexes
1991
Paraoxonase Genes and Disease
1999
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
1993 Standout
Protective Effect of Paraoxonase Activity in High-Density Lipoproteins against Erythrocyte Membranes Peroxidation: A Comparison between Healthy Subjects and Type 1 Diabetic Patients
2004
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
2017 Standout
Serum paraoxonase activity and its relationship to diabetic complications in patients with non—insulin-dependent diabetes mellitus
1998
Diabetic dyslipidaemia: from basic research to clinical practice*
2003
Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland
1998
Prevalence of the metabolic syndrome in drug‐treated hypertensive patients and control subjects
1999
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.
1996
Cigarette Smoke Extract Inhibits Plasma Paraoxonase Activity by Modification of the Enzyme's Free Thiols
1997
Association of Depression and Diabetes Complications: A Meta-Analysis
2001
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
1999 Standout
The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel
2002 StandoutNatureNobel
Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk
2012
Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
1997
The Relationship of Autonomic Neuropathy to Other Diabetic Complications
1993
Presence of paraoxonase in human interstitial fluid
1997
Is paraoxonase related to atherosclerosis
1993
Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study
2001
Type 2 diabetes
2017 Standout
Hydrolysis of platelet-activating factor by human serum paraoxonase
2001
Global and societal implications of the diabetes epidemic
2001 StandoutNature
Prevalence of the Metabolic Syndrome Among US Adults
2002 Standout
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data
1998
Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes
1997
Differential effects of smoking on myocardial infarction risk according to to the Gln/Arg 192 variants of the human paraoxonase gene
2000
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
1999 Standout
The metabolic syndrome—a new worldwide definition
2005 Standout
Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits
2000
HDL, its enzymes and its potential to influence lipid peroxidation
1995
New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis
2009
Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity
1993
Recurrent miscarriage
2006 Standout
Atherosclerosis
2000 StandoutNature
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effects of western diet feeding
2000
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
1997
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
1995 Standout
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
1998 Standout
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
1987 Standout
Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study
1999
Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein
1991 Standout
Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
1999
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment
1994
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
2006 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation
2001
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
1995
The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese
1998
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
2005 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II
2002
Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL
1996
Reduced Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice Following Consumption of Red Wine, or Its Polyphenols Quercetin or Catechin, Is Associated With Reduced Susceptibility of LDL to Oxidation and Aggregation
1997
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
1996
Genetic Polymorphism of Paraoxonase and the Risk of Coronary Heart Disease
1997
Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients
2000
Pharmacological and surgical treatment of obesity.
2004
Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
2015 StandoutNobel
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
1998 Standout
Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice
2003
Hypochlorous Acid Promoted Platinum Drug Chemotherapy by Myeloperoxidase-Encapsulated Therapeutic Metal Phenolic Nanoparticles
2018
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
2005 Standout
Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition
2004
Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins
1995
Can We Apply the National Cholesterol Education Program Adult Treatment Panel Definition of the Metabolic Syndrome to Asians?
2004
Paraoxonase and Atherosclerosis
2001 Standout
Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions
2000 Standout
Reduced Postprandial Serum Paraoxonase Activity After a Meal Rich in Used Cooking Fat
1999
Kidney Hypoxia, Attributable to Increased Oxygen Consumption, Induces Nephropathy Independently of Hyperglycemia and Oxidative Stress
2013
Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases
2015 Standout
Diabetic Autonomic Neuropathy: the Prevalence of Impaired Heart Rate Variability in a Geographically Defined Population
1989
Abnormal Reverse Cholesterol Transport in Controlled Type II Diabetic Patients
1995
Paraoxonase-Gene Polymorphisms Associated with Coronary Heart Disease: Support for the Oxidative Damage Hypothesis?
1998
Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities
1998
The system of care for the diabetic foot: objectives, outcomes, and opportunities
2013
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
2003 Standout
Diabetic Autonomic Neuropathy
2003 Standout
Adenoviral transfer of HIF-1α enhances vascular responses to critical limb ischemia in diabetic mice
2009 StandoutNobel
Serum Paraoxonase After Myocardial Infarction
1999
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
1999
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance
2003
The Prevalence of Comorbid Depression in Adults With Diabetes
2001 Standout
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
1993 Standout
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
2000
Decrease of serum paraoxonase activity in chronic renal failure.
1998
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
2002
Mediators of Depression in Adults with Diabetes
1996
Works of Peter Winocour being referenced
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with Type 1 (insulin-dependent) diabetes mellitus
1992
Placebo‐controlled Trial of the Effects of Guar Gum and Metformin on Fasting Blood Glucose and Serum Lipids in Obese, Type 2 Diabetic Patients
1990
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in Type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia
1992
Apolipoprotein E polymorphism and lipoproteins in insulin-treated diabetes mellitus
1989
Microalbuminuria and associated cardiovascular risk factors in the community
1992
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
1991 Standout
Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins
1992
Double‐blind Placebo‐controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus
1990
Association of British Clinical Diabetologists (ABCD): survey of specialist diabetes care services in the UK, 2000. 3. Podiatry services and related foot care issues
2002
Oxidative stress in early diabetic nephropathy: fueling the fire
2010
Mechanisms of Disease: the hypoxic tubular hypothesis of diabetic nephropathy
2008
Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia.
1993
A psychometric evaluation of adult patients with type 1 (insulin-dependent) diabetes mellitus: prevalence of psychological dysfunction and relationship to demographic variables, metabolic control and complications.
1990
Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus.
1992
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus.
1987
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association
1993
Relation between insulinemia, body mass index, and lipoprotein composition in healthy, nondiabetic men and women.
1992
Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK.
1997
The Relationship Between Autonomic Neuropathy and Urinary Sodium and Albumin Excretion in Insulin‐Treated Diabetics
1986